Navigation Links
Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
Date:9/28/2011

e include forward-looking statements (including, without limitation, statements concerning the timing, scope and outcomes of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact  
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
(Date:5/5/2015)... VetStem Biopharma, proudly announces former ... Schaffer, DVM, as Director of Veterinary Professional Services. ... experience in the veterinary regenerative medicine field Dr ... veterinarian lead organization”. Dr. Alexis Nahama, President ... be responsible for all technical activities in relationship ...
(Date:5/5/2015)... MILFORD, Mass. , May 5, 2015 ... a strategic alliance which offers a first-of-its-kind platform that ... patient access to lab results, transforms the way patients ... Luminate Health provides a HIPAA-compliant ... patients to access, manage, and understand their lab results, ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... 3, 2011  Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: ... to the early diagnosis, and possibly treatment of, Type ... Class II Epitope Hybrids Derived from Proinsulin and GAD ... appears in the April issue of the international peer-reviewed ...
... SAN DIEGO, May 3, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing. ... the Toronto Convention Center.   James Levine, ...
... VIEW, Calif., May 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... first quarter ended March 31, 2011. The net ... $17.6 million compared to a net loss of $14.1 million ... first quarter ended March 31, 2011 was related primarily to ...
Cached Biology Technology:Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 2Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 3Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 4Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 2Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... This release is available in German . ... channels and ion pumps, and thus specifically control them with ... J. Zlch Prize 2012 to four scientists who initiated and ... optogenetics: Ernst Bamberg of the Max Planck Institute of Biophysics ...
... lot of all the hens in the flock, but the ... sperm - and thus more chicks. This sounds natural, but ... of years, people have tinkered with the development of domestic ... large muscle mass and increased egg-laying, we have at the ...
... autism researchers in the University of North Carolina School of ... latest round of funding from the National Institutes of Health,s ... was ranked No. 2 among the top 25 institutions in ... Autism Coordinating Committee, is one of only two institutions that ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4For the rooster, size matters 22 UNC faculty receive Autism Centers of Excellence grants for new research 22 UNC faculty receive Autism Centers of Excellence grants for new research 3
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S ... The gamma secretase is a multiprotein ... and Pen-2; all four proteins are ... gamma secretase complex catalyzes cleavage of ...
... Bio-Beads S-X media are ... for size exclusion chromatography of ... that require organic eluents. The ... toluene, xylene, carbon tetrachloride, dimethylformamide, ...
Biology Products: